Gocatamig

BIOLOGICAL3 trials

Sponsors

Harpoon Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA), Merck Sharp & Dohme LLC

Conditions

Neuroendocrine CarcinomaSmall Cell Lung CancerSmall Cell Lung Cancer Extensive StageSmall-Cell Lung Cancer

Phase 1

A Study in Participants With Advanced Cancers Associated With Expression of DLL3 (MK-6070-001/HPN328-4001)

Active, not recruitingNCT04471727

Harpoon Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)Neuroendocrine Carcinoma, Small-Cell Lung Cancer

Start: 2020-12-14End: 2028-01-28Target: 232Updated: 2026-02-24

A Study to Evaluate the Safety and Efficacy of Gocatamig (MK-6070) and Ifinatamab Deruxtecan (I-DXd) in Participants With Relapsed/Refractory Extensive-Stage Small Cell Lung Cancer (MK-6070-002)

RecruitingNCT06780137

Merck Sharp & Dohme LLCSmall Cell Lung Cancer

Start: 2025-02-27End: 2030-01-17Target: 262Updated: 2026-03-24

A Clinical Study of Gocatamig (MK-6070) and Infinatamab Deruxtecan (MK-2400) in People With Small Cell Lung Cancer (MK-6070-003)

RecruitingNCT07227597

Merck Sharp & Dohme LLCSmall Cell Lung Cancer Extensive Stage

Start: 2026-01-29End: 2030-12-30Target: 170Updated: 2026-03-30

Related Papers

Data from Preclinical Activity of the DLL3-Targeted T-cell Engager MK-6070 in Neuroendocrine Prostate Cancer

2026-02-04

Preclinical activity of the DLL3-targeted T cell engager MK-6070 in neuroendocrine prostate cancer.

2025-10-03

Updated results from a phase 1/2 study of HPN328, a tri-specific, half-life (T1/2) extended DLL3-targeting T-cell engager in patients (pts) with small cell lung cancer (SCLC) and other neuroendocrine cancers (NEC).

Journal of Clinical Oncology2024-06-0127 citations

Interim results from a phase 1/2 study of HPN328, a tri-specific, half-life (T1/2) extended DLL3-targeting T-cell engager, in patients (pts) with neuroendocrine prostate cancer (NEPC) and other neuroendocrine neoplasms (NEN).

Journal of Clinical Oncology2024-01-2925 citations

Abstract 5070: Anti-tumor activity of HPN328, a DLL3-targeting tri-specific, half-life extended T cell engager, is enhanced by combining with an anti-PD-L1 antibody in an immunocompetent mouse model

Cancer Research2023-04-042 citations

Abstract 4131: Long-term anti-tumor immunity induced by of HPN328, a DLL3-targeting trispecific, half-life extended T cell engager, in a preclinical immunocompetent mouse model

Cancer Research2023-04-041 citations

Interim results of an ongoing phase 1/2a study of HPN328, a tri-specific, half-life extended, DLL3-targeting, T-cell engager, in patients with small cell lung cancer and other neuroendocrine cancers.

Journal of Clinical Oncology2022-06-0145 citations

Abstract 1573: Combinatorial antitumor effects of CD3-based trispecific T cell activating constructs (TriTACs) and checkpoint inhibitors in preclinical models

Cancer Research2021-07-012 citations